Evaluation of Empirical Meropenem Bolus Protocol in Pseudomonas aeruginosa: A Three-Year Analysis in Tertiary Intensive Care Unit

References

• Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463–70. doi:10.1073/pnas.1717295115
   PubMed Web of Science ®Google Scholar
• Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. 2017;12:12. doi:10.1371/journal.pone.0189621
   Web of Science ®Google Scholar
• Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control. 2019;8(1):137. doi:10.1186/s13756-019-0590-7
   PubMed Web of Science ®Google Scholar
• Timsit JF, Bassetti M, Cremer O, et al. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Med. 2019;45(2):172–189. doi:10.1007/s00134-019-05520-5
   PubMed Web of Science ®Google Scholar
• Saharman YR, Karuniawati A, Severin JA, Verbrugh HA. Infections and antimicrobial resistance in intensive care units in lower-middle income countries: a scoping review. Antimicrob Resist Infect Control. 2021;10(1):22. doi:10.1186/s13756-020-00871-x
   PubMedGoogle Scholar
• Saharman YR, Pelegrin AC, Karuniawati A, et al. Epidemiology and characterisation of carbapenem-non-susceptible Pseudomonas aeruginosa in a large intensive care unit in Jakarta, Indonesia. Int J Antimicrob Agents. 2019;54(5):655–660. doi:10.1016/j.ijantimicag.2019.08.003
   PubMed Web of Science ®Google Scholar
• Budayanti NS, Aisyah DN, Fatmawati NND, Tarini NMA, Kozlakidis Z, Adisasmito W. Identification and distribution of pathogens in a major tertiary hospital of Indonesia. Front Public Heal. 2020;7:395. doi:10.3389/fpubh.2019.00395
   PubMed Web of Science ®Google Scholar
• Khilnani GC, Zirpe K, Hadda V, et al. Guidelines for antibiotic prescription in intensive care unit. Indian J Crit Care Med. 2019;23(Suppl 1):1–63. doi:10.5005/jp-journals-10071-23101
   PubMed Web of Science ®Google Scholar
• Patrier J, Timsit JF. Carbapenem use in critically ill patients. Curr Opin Infect Dis. 2020;33(1):86–91. doi:10.1097/QCO.0000000000000622
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. The core elements of hospital antibiotic stewardship programs: antibiotic stewardship program assessment tool; 2019. Available from: https://www.cdc.gov/antibiotic-use/healthcare/pdfs/assessment-tool-P.pdf. Accessed October 27, 2021.
   Google Scholar
• Wunderink RG, Srinivasan A, Barie PS, et al. Antibiotic stewardship in the intensive care unit: an official American Thoracic Society Workshop report in collaboration with the AACN, CHEST, CDC, and SCCM. Ann Am Thorac Soc. 2020;17(5):531–540. doi:10.1513/AnnalsATS.202003-188ST
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D. Causes and outcomes of sepsis in Southeast Asia: a multinational multicentre cross-sectional study. Lancet Glob Heal. 2017;5(2):e157.
   PubMed Web of Science ®Google Scholar
• Luyt CE, Hékimian G, Koulenti D, Chastre J. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018;24(5):333–338. doi:10.1097/MCC.0000000000000526
   Web of Science ®Google Scholar
• Shields RK, Zhou Y, Kanakamedala H, Cai B. Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia. BMC Infect Dis. 2021;21(1):572. doi:10.1186/s12879-021-06229-x
   PubMed Web of Science ®Google Scholar
• Lertwattanachai T, Montakantikul P, Tangsujaritvijit V, et al. Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial. J Intensive Care. 2020;8:1. doi:10.1186/s40560-020-00442-7
   PubMed Web of Science ®Google Scholar
• Kothekar AT, Divatia JV, Myatra SN, et al. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria. Ann Intensive Care. 2020;10(1):4. doi:10.1186/s13613-019-0622-8
   PubMed Web of Science ®Google Scholar
• Monajati M, Ala S, Aliyali M, et al. Clinical effectiveness of a high dose versus the standard dose of meropenem in ventilator-associated pneumonia caused by multidrugresistant bacteria: a randomized, single-blind clinical trial. Infect Disord Drug Targets. 2021;21(2):274–283. doi:10.2174/1871526520666200227102013
   PubMedGoogle Scholar
• Song X, Wu Y, Cao L, Yao D, Long M. Is meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? A pharmacokinetic/pharmacodynamic modeling with Monte Carlo simulation. Front Microbiol. 2019:2777. doi:10.3389/fmicb.2019.02777
   PubMed Web of Science ®Google Scholar
• Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One. 2018;13:7. doi:10.1371/journal.pone.0201667
   Web of Science ®Google Scholar
• Uricová J, Kacířová I, Brozmanová H. Meropenem serum concentrations in intensive care patients: a retrospective analysis. Czech Slovak Pharm. 2020;69(5–6):230–236.
   PubMedGoogle Scholar
• Hamdiyati R, Pinatih KJP, Fatmawati NND. Microbes and their susceptibility pattern to antibiotics in intensive care unit (ICU) Sanglah Hospital Denpasar Bali at August 2013 until October 2013. E-Jurnal Med. 2016;5(4):1–6.
   Google Scholar
• Dharmayanti IGAMP, Sukrama DM. Characteristics of Pseudomonas aeruginosa and its susceptibility pattern to antibiotics in intensive care unit (ICU) of Sanglah General Hospital in November 2014-January 2015. E-Jurnal Med. 2019;8:4.
   Google Scholar
• Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A, Jones RN. Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY antimicrobial surveillance program, 1997–2016. Open Forum Infect Dis. 2019;6(Suppl 1):S63. doi:10.1093/ofid/ofy343
   PubMed Web of Science ®Google Scholar
• Piérard D, Stone GG. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018). BMC Infect Dis. 2021;21(1):600. doi:10.1186/s12879-021-06153-0
   PubMed Web of Science ®Google Scholar